# Harrow Inc. (HROW)

Source: https://www.quantisnow.com/company/HROW
Generated: 2026-11-18T12:59:33.509Z

- Ticker: HROW
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001360214
- Website: harrowinc.com

## About

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.

## Latest HROW news and filings

- 2026-11-16 21:20 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6794357)
- 2026-11-12 18:06 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-harrow-inc-6787315)
- 2026-11-12 12:00 UTC [Conference Announcement] [Harrow to Participate in Two Investor Conferences in November](https://www.quantisnow.com/insight/harrow-to-participate-in-two-investor-conferences-in-november-6785989)
- 2026-11-09 22:12 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Harrow Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-harrow-inc-6782037)
- 2026-11-09 21:13 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-results-of-operations-and-6781439)
- 2026-11-09 21:02 UTC [Earnings] [Harrow Announces Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/harrow-announces-third-quarter-2026-financial-results-6781069)
- 2026-11-06 21:05 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-harrow-inc-6778856)
- 2026-11-02 14:00 UTC [PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio](https://www.quantisnow.com/insight/phil-partners-with-harrow-to-power-harrowrx-one-prescribing-destination-6766425)
- 2026-11-02 12:00 UTC [Harrow Launches HarrowRx Platform](https://www.quantisnow.com/insight/harrow-launches-harrowrx-platform-6766004)
- 2026-10-26 11:00 UTC [Earnings Date] [Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026](https://www.quantisnow.com/insight/harrow-to-report-third-quarter-2026-financial-results-after-market-6756867)
- 2026-10-05 11:32 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-entry-into-a-material-6735924)
- 2026-10-05 11:00 UTC [Leadership Update] [Harrow Closes Acquisition of TYRVAYA®](https://www.quantisnow.com/insight/harrow-closes-acquisition-of-tyrvaya-6735850)
- 2026-09-30 11:00 UTC [Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO](https://www.quantisnow.com/insight/harrow-ophthalmic-portfolio-highlighted-in-15-scientific-presentations-at-aaopt-6729870)
- 2026-09-09 13:33 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Harrow with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-harrow-with-a-new-price-6709672)
- 2026-09-04 20:45 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-leadership-update-financial-statements-6707019)
- 2026-09-01 11:00 UTC [Conference Announcement] [Harrow to Participate in Three Investor Conferences in September](https://www.quantisnow.com/insight/harrow-to-participate-in-three-investor-conferences-in-september-6700427)
- 2026-08-20 11:00 UTC [Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections](https://www.quantisnow.com/insight/harrow-announces-iheezo-data-in-patient-reported-discomfort-following-intravitreal-injections-6689304)
- 2026-08-17 21:47 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Shojaei Amir exercised 11,250 shares at a strike of $35.96 and sold $450,000 worth of shares (11,250 units at $40.00) (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-shojaei-amir-exercised-11250-shares-at-a-6685491)
- 2026-08-10 20:28 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Harrow Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-harrow-inc-6673940)
- 2026-08-10 20:10 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-results-of-operations-and-6673748)
- 2026-08-10 20:05 UTC [Earnings Date] [Harrow Announces Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/harrow-announces-second-quarter-2026-financial-results-6673524)
- 2026-08-06 11:15 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-entry-into-a-material-6667225)
- 2026-08-06 11:00 UTC [Mergers & Acquisitions] [Harrow Acquires Global Rights to TYRVAYA®,  the First and Only FDA-Approved Nasal Spray for Dry Eye Disease](https://www.quantisnow.com/insight/harrow-acquires-global-rights-to-tyrvaya-the-first-and-only-6667042)
- 2026-07-27 11:00 UTC [Earnings Date] [Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026](https://www.quantisnow.com/insight/harrow-to-report-second-quarter-2026-financial-results-after-market-6648904)
- 2026-07-20 12:00 UTC [Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026](https://www.quantisnow.com/insight/samsung-bioepis-and-harrow-present-interim-data-from-a-large-scale-6641914)
- 2026-07-20 11:00 UTC [Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting](https://www.quantisnow.com/insight/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-6641808)
- 2026-07-01 11:00 UTC [Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow](https://www.quantisnow.com/insight/samsung-bioepis-relaunches-byooviz-ranibizumab-nuna-in-the-united-states-in-6621728)
- 2026-06-22 23:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Sternberg Perry J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sternberg-perry-j-6611415)
- 2026-06-22 23:50 UTC [SEC Form 4] [SEC Form 4 filed by Director Graves Adrienne L](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-graves-adrienne-l-6611414)
- 2026-06-22 23:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Silvernail Lauren P](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-silvernail-lauren-p-6611413)
- 2026-06-22 11:30 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-submission-of-matters-to-6609993)
- 2026-06-10 11:00 UTC [Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare](https://www.quantisnow.com/insight/harrow-re-launches-verkazia-cyclosporine-ophthalmic-emulsion-01-for-vernal-keratoconjunctivitis-6596298)
- 2026-06-03 13:15 UTC [SEC Form 8-K] [Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6586149)
- 2026-05-27 11:00 UTC [Conference Announcement] [Harrow to Present at William Blair's 46th Annual Growth Stock Conference](https://www.quantisnow.com/insight/harrow-to-present-at-william-blairs-46th-annual-growth-stock-6573753)
- 2026-05-19 11:00 UTC [Insider Buy] [Director Silvernail Lauren P bought $31,000 worth of shares (1,000 units at $31.00) (SEC Form 4)](https://www.quantisnow.com/insight/director-silvernail-lauren-p-bought-31000-worth-of-shares-1000-6561598)
- 2026-05-19 11:00 UTC [Insider Buy] [Director Graves Adrienne L bought $31,070 worth of shares (1,000 units at $31.07) (SEC Form 4)](https://www.quantisnow.com/insight/director-graves-adrienne-l-bought-31070-worth-of-shares-1000-6561596)
- 2026-05-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Shojaei Amir](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-shojaei-amir-6560808)
- 2026-05-15 11:01 UTC [Insider Buy] [CHIEF EXECUTIVE OFFICER Baum Mark L bought $302,000 worth of shares (10,000 units at $30.20), increasing direct ownership by 0.33% to 2,996,130 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-baum-mark-l-bought-302000-worth-of-6555559)
- 2026-05-15 11:00 UTC [Insider Buy] [PRESIDENT AND CFO Boll Andrew R. bought $104,650 worth of shares (3,500 units at $29.90), increasing direct ownership by 0.43% to 814,679 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-cfo-boll-andrew-r-bought-104650-worth-of-6555551)
- 2026-05-11 20:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Harrow Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-harrow-inc-6545362)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/HROW
- Earnings history: https://www.quantisnow.com/earnings/HROW
- Dividend history: https://www.quantisnow.com/dividends/HROW
- Insider transactions: https://www.quantisnow.com/insiders/HROW
- Options chain: https://www.quantisnow.com/options/HROW
- SEC 8-K filings only: https://www.quantisnow.com/company/HROW/8-k
- RSS and alerts for HROW: https://www.quantisnow.com/docs/rss-feeds.md
